Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:RNAZ

TransCode Therapeutics - RNAZ Stock Forecast, Price & News

$0.40
-0.09 (-18.37%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.37
$0.45
50-Day Range
$0.48
$1.23
52-Week Range
$0.37
$3.13
Volume
366,767 shs
Average Volume
210,608 shs
Market Capitalization
$5.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

TransCode Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,400.0% Upside
$6.00 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of TransCode Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$23,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.34) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

RNAZ stock logo

About TransCode Therapeutics (NASDAQ:RNAZ) Stock

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Receive RNAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNAZ Stock News Headlines

TransCode Therapeutics, Inc. (RNAZ)
TransCode Therapeutics reports Q2 results
TransCode Therapeutics reports Q1 results
TransCode Falls on Q1 Figures
See More Headlines
Receive RNAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNAZ Company Calendar

Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNAZ
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-6,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.58 per share

Miscellaneous

Free Float
11,056,000
Market Cap
$5.19 million
Optionable
Not Optionable
Beta
0.62

Key Executives

  • Mr. Robert Michael Dudley (Age 71)
    Co-Founder, CEO, Pres & Director
    Comp: $495.48k
  • Mr. Thomas A. Fitzgerald M.B.A. (Age 70)
    CFO, VP of Admin. & Director
    Comp: $317.61k
  • Dr. Zdravka Medarova Ph.D. (Age 47)
    Co-Founder & CTO
  • Dr. Anna Moore Ph.D. (Age 60)
    Co-Founder, Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Qiyong Peter Liu Ph.D. (Age 58)
    VP of R&D and Chief Scientist
  • Mr. Alan Freidman
    VP of Investor Relations













RNAZ Stock - Frequently Asked Questions

Should I buy or sell TransCode Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransCode Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNAZ shares.
View RNAZ analyst ratings
or view top-rated stocks.

What is TransCode Therapeutics' stock price forecast for 2023?

1 brokerages have issued 1-year price targets for TransCode Therapeutics' shares. Their RNAZ share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,400.0% from the stock's current price.
View analysts price targets for RNAZ
or view top-rated stocks among Wall Street analysts.

How have RNAZ shares performed in 2022?

TransCode Therapeutics' stock was trading at $2.54 on January 1st, 2022. Since then, RNAZ stock has decreased by 84.3% and is now trading at $0.40.
View the best growth stocks for 2022 here
.

Are investors shorting TransCode Therapeutics?

TransCode Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 7,600 shares, a drop of 96.5% from the October 31st total of 218,800 shares. Based on an average trading volume of 654,100 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the shares of the stock are short sold.
View TransCode Therapeutics' Short Interest
.

When is TransCode Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our RNAZ earnings forecast
.

When did TransCode Therapeutics IPO?

(RNAZ) raised $25 million in an initial public offering (IPO) on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share.

What is TransCode Therapeutics' stock symbol?

TransCode Therapeutics trades on the NASDAQ under the ticker symbol "RNAZ."

How do I buy shares of TransCode Therapeutics?

Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransCode Therapeutics' stock price today?

One share of RNAZ stock can currently be purchased for approximately $0.40.

How much money does TransCode Therapeutics make?

TransCode Therapeutics (NASDAQ:RNAZ) has a market capitalization of $5.19 million. The company earns $-6,840,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How can I contact TransCode Therapeutics?

TransCode Therapeutics' mailing address is 6 LIBERTY SQUARE 2382, BOSTON MA, 02109. The official website for the company is www.transcodetherapeutics.com. The company can be reached via phone at 857-837-3099.

This page (NASDAQ:RNAZ) was last updated on 11/28/2022 by MarketBeat.com Staff